Analyst Reco. REGENXBIO Inc.

Equities

RGNX

US75901B1070

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
16.83 ^USD	+1.14%		+3.95%	-6.24%

28/03	REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD	CI
18/03	Transcript : REGENXBIO Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 03:30 PM

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Initiates REGENXBIO With Buy Rating, $36 Price Target	11/03	MT
RBC Upgrades REGENXBIO to Outperform From Sector Perform, Lifts Price Target to $35 From $20, 'Impressed by Recent Execution,' Keeps Speculative Risk	08/03	MT
Leerink Partners Upgrades REGENXBIO to Outperform From Market Perform	06/03	MT
Baird Adjusts Price Target on REGENXBIO to $39 From $34, Maintains Outperform Rating	06/03	MT
UBS Cuts REGENXBIO Price Target to $43 From $47, Maintains Buy Rating	17/01	MT
Wedbush Lifts REGENXBIO's PT to $21 From $20 After Higher-Than-Expected Q3 Revenue, Announced Restructuring; Keeps Neutral Rating	14/11	MT
Stifel Initiates REGENXBIO With Buy Rating, Price Target is $35	01/11	MT
Morgan Stanley Adjusts Price Target on REGENXBIO to $42 From $43, Maintains Overweight Rating	29/23/29	MT
Baird Initiates REGENXBIO at Outperform With $42 Price Target	02/23/02	MT
Morgan Stanley Adjusts Price Target on Regenxbio to $43 From $46, Maintains Overweight Rating	09/23/09	MT
Chardan Research Lowers REGENXBIO's Price Target to $55 From $61, Buy Rating Kept	05/23/05	MT
Wedbush Trims REGENXBIO's Price Target to $20 From $21, Keeps Neutral Rating	05/23/05	MT
RBC Cuts Price Target on REGENXBIO to $20 From $22, Maintains Sector Perform, Speculative Risk	04/23/04	MT
RBC Capital Adjusts REGENXBIO Price Target to $22 From $25, Maintains Sector Perform - Speculative Risk Rating	06/23/06	MT
Morgan Stanley Trims Price Target on REGENXBIO to $46 From $50, Maintains Overweight Rating	06/23/06	MT
Wedbush Raises REGENXBIO's Price Target to $21 From $18 After Including RGX-111/MPS I in Model., Keeps Neutral Rating	01/23/01	MT
SVB Securities Adjusts Price Target on REGENXBIO to $14 From $15, Maintains Market Perform Rating	23/23/23	MT
Morgan Stanley Adjusts Price Target on REGENXBIO to $50 From $52, Maintains Overweight Rating	21/22/21	MT
SVB Securities Adjusts Price Target on REGENXBIO to $14 From $13, Maintains Market Perform Rating	04/22/04	MT
RBC Lowers REGENXBIO's PT to $25 From $29, Keeps Sector Perform, Speculative Risk Rating	04/22/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. REGENXBIO Inc.

Equities

RGNX

US75901B1070

Analyst Reco.

Filters